• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 14, 2018

View Archived Issues

Biogen bails on AGTC after failed XLRS gene therapy test, shares sink

Applied Genetic Technologies Corp. (AGTC) dropped two pieces of bad news following Wednesday's market close. The Gainesville, Fla.-based company said it was halting development of rAAV2tYF-CB-hRS1, its adeno-associated virus (AAV)-based RS1 gene therapy for X-linked retinoschisis (XLRS), after top-line interim data from its phase I/II trial showed no sign of clinical activity at six months. AGTC also revealed that Biogen Inc. was walking away from their three-year-old, potential $1 billion collaboration and returning full rights to the clinical-stage XLRS and X-linked retinitis pigmentosa (XLRP) programs and discovery programs in adrenoleukodystrophy (ALD) and two ophthalmic targets, effective March 8, 2019. Read More

Huge sigh from generics as FDA withdraws 5-year-old labeling proposal

Sponsors of generics likely heaved a big sigh of relief Thursday when the FDA said it was tossing a controversial proposed rule that would have put generics on the hook for state failure-to-warn claims. Read More

Amag expands hematology portfolio with $415M Perosphere buy

Taking advantage of what Amag Pharmaceuticals Inc. President and CEO Bill Heiden called a "significant growth opportunity," the company is acquiring anticoagulant reversal agent developer Perosphere Pharmaceuticals Inc. for $50 million up front and up to $365 million in potential milestone payments. Analysts lauded the intent of the deal, praising its potential to further diversify Amag's portfolio and complement its oral iron therapy, Feraheme (ferumoxytol). But differentiating the phase II candidate, ciraparantag, from already-approved reversal agents Praxbind (idarucizumab) and Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo), will be key to the program's success, they said. Read More

No escaping Brexit: Industry leaders talk impact, preparation at annual Genesis Conference

LONDON – Don't mention the B word: On a day when anxiety levels over Brexit ratcheted further upward, the if, how and when of the U.K.'s leaving the EU suffused the atmosphere at the 18th annual Genesis conference in London on Thursday. Read More

Fetal tissue hearing turns into skirmish on abortion, new research way sought

A scrappy joint meeting of the House Subcommittee on Healthcare, Benefits, and Administrative Rules and the House Subcommittee on Government Operations featured opposing views of current science with regard to fetal tissue research in a two-hour-plus session that included Chairman Rep. Mark Meadows (R.-N. Carolina) objecting to the sale of "baby parts." Read More

Gottlieb: 'Shared obligation' for drug-, device makers to advance health and safety

WASHINGTON – U.S. FDA commissioner Scott Gottlieb had some pointed words for drugmakers regarding data integrity at a Food and Drug Law Institute (FDLI) meeting in the nation's capital, while Bill Maisel, the acting director of the agency's device center, had better news for device makers on regulatory harmonization efforts. Read More

Regulatory front

The U.S. Patent and Trademark Appeal Board (PTAB) found all the claims in two formulation patents for Sanofi SA's Lantus (insulin glargine) unpatentable as the result of an inter partes review (IPR) requested by Mylan NV, of Hertfordshire, U.K.  Read More

Financings

Kuros Biosciences Ltd., of Schlieren, Switzerland, disclosed total gross proceeds of CHF16.1 million (US$16.2 million) in its rights offering and placement of 6.5 million new registered shares priced at CHF2.50 apiece. Read More

Other news to note

VLP Therapeutics LLC, of Gaithersburg, Md., said the Global Health Innovative Technology Fund awarded the firm a $3.9 million grant to further develop a tetravalent dengue virus-like particle vaccine. Funding will enable further development and manufacturing. Read More

Clinical data for Dec. 13, 2018

Read More

Regulatory actions for Dec. 13, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe